[1] Callaghan JT, Bergstrom RF, Ptak LR, et al.Olanzapine - Pharmacokinetic and pharmacodynamic profile[J]. Clin Pharmacokinet, 1999, 37(3): 177-193. [2] 袁国锋, 俞玉礼. 奥氮平治疗老年精神分裂症患者的疗效观察及对心电图的影响[J]. 中国临床药理学与治疗学, 2011,16(3): 304-307. [3] 吴小立, 王继辉, 钟智勇,等.阿立哌唑与奥氮平对首发精神分裂症急性期疗效及对催乳素的影响[J].中国临床药理学与治疗学, 2011,16(9): 1016-1020. [4] Bhana N, Foster RH, Olney R, et al.Olanzapine - An updated review of its use in the management of schizophrenia[J].Drugs, 2001, 61(1): 111-161. [5] 和喜梅, 刘学武. 临床个体化用药的研究现状和评价[J]. 中国临床药理学与治疗学, 2003, 8(2): 237-240. [6] FDA: Guidance for Industry: Bioanalytical Method Validation. U.S. Department of Health and Human Services, Food and Drug Administration Center for Drug Evaluation and Research (CDER)[EB/OL], 2001. http://www.fda.gov/cder/guidance/index. htm/. [7] 徐英, 陈崇崇, 杨莉, 等. 基于胆汁酸代谢网络分析中药黄药子的肝毒性[J]. 药学学报, 2011, 46(1): 39-44. [8] 王毅, 俞凌燕, 范骁辉, 等. 一种基于近红外光谱的天然产物抗氧化活性预测评价方法[J]. 光谱学与光谱分析, 2009,29(9) :2401-2404. [9] 冯伟峰, 孙升云, 刘康丽,等. 基于PLS模型的血尿酸与代谢综合征各组分的相关性研究[J]. 广东医学, 2010, 31(21): 2772-2775. [10] Phapale PB, Kim SD, Lee HW, et al.An Integrative Approach for Identifying a Metabolic Phenotype Predictive of Individualized Pharmacokinetics of Tacrolimus[J]. Clin Pharmacol Ther, 2010, 87(4): 426-436. [11] Robertson MD, McMullin MM. Olanzapine concentrations in clinical serum and postmortem blood specimens-When does therapeutic become toxic[J]? J Forensic Sci, 2000,45(2):418-421. |